Genetic testing and biomarkers are reshaping cancer care through risk stratification and precision medicine. Advances in genetic profiling enable the identification of hereditary cancer syndromes, guiding preventive measures and early interventions. Biomarkers such as PD-L1, HER2, and EGFR are integral to targeted therapies, improving efficacy and reducing side effects. Liquid biopsy and genomic sequencing provide real-time monitoring of cancer progression and treatment response. Research focuses on discovering novel biomarkers and expanding the utility of genetic testing, making cancer care more individualized and effective.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China